Matinas BioPharma Holdings, Inc. (MTNB) Stock: Why It’s Headed For The Top


Matinas BioPharma Holdings, Inc. (MTNB) is trending up in the market in today’s trading session. The stock, one that is focused on the biotechnology space, is presently priced at $1.30 after heading up 8.33% so far in today’s session. When it comes to biotech companies, there are quite a few aspects that have the ability to generate price movement in the market. One of the most common is news. Here are the most recent trending headlines centered around MTNB:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-15-19 08:45AM Matinas BioPharma Announces Pricing of Public Offering of Common Stock
Mar-14-19 05:02PM Matinas BioPharma Announces Proposed Public Offering of Common Stock
Feb-25-19 08:05AM Prominent Cardiovascular Expert, James J. Ferguson, M.D., FACC, FAHA Joins Matinas BioPharma as Chief Medical Officer
Jan-16-19 09:00AM Biotech Breaking Out
Jan-10-19 08:00AM Matinas BioPharma Announces a Research Evaluation with Top Global Pharma Company Based on Its Proprietary Drug Delivery Platform

However, any time investors are making a decision with regard to investing, prospective investors should take a look at much more than just news, especially in the highly speculative biotech sector. Here’s what’s happening with Matinas BioPharma Holdings, Inc..

The Performance That We’ve Seen From MTNB

While a move up on a single session, like the gain that we’re seeing from Matinas BioPharma Holdings, Inc. might make some investors excited, a single session gain by itself should not be the reason for a decision to, or not to, invest in a company. It is always smart to look into trends just a single session. In the case of MTNB, below are the movements that we’ve seen:

  • Past 5 Trading Sessions – In the last five trading sessions, MTNB has generated a change in value in the amount of 1.56%.
  • Past Month – The ROI from Matinas BioPharma Holdings, Inc. over the last 30 days has been 22.64%.
  • Past 3 Months – Throughout the past quarter, the stock has generated a ROI that comes to 64.56%
  • Past Six Months – Throughout the previous 6 months, investors have seen a change that works out to 180.66% from the company.
  • This Year So Far – Since the open of this year MTNB has produced a return of 118.49%.
  • Full Year – Lastly, throughout the past full year, we have seen a change of 26.21% out of MTNB. Throughout this period of time, the stock has traded at a high of -13.33% and a low price of 301.61%.

Ratios Worth Paying Attention To

Looking at various ratios having to do with a stock generally gives prospective traders a look of just how risky and/or rewarding a an investment option might be. Here are a few of the important ratios to think about when digging into MTNB.

Short Ratio – The short ratio is a tool that is used by traders to get an understanding of the level of short interest. The higher this ratio, the more investors are expecting that the stock is going to fall. Throughout the sector, biotechnology stocks tend to carry a higher short ratio. However, we also tend to see a lot of short squeezes in the sector. Nonetheless, in regard to Matinas BioPharma Holdings, Inc., the stock’s short ratio is 4.96.

Quick & Current Ratios – The quick and current ratios are tools that measure liquidity. Essentially, they measure If a company is able to cover its debts when they come due using quick assets or current assets. In the biotechnology space, several companies rely heavily on continued investor support, the current and quick ratios can be upsetting. However, several better companies in the biotechnology industry do have good current and quick ratios. As it relates to MTNB, the quick and current ratios add up to 2.90 and 2.90 respectively.  

Book To Share Value – The book to share value ratio compares the current book value of assets owned by the company to the price of shares. In this particular case, that ratio is -0.01.

Cash To Share Value – The cash to share value comparison compares the amount of cash the company has on hand to the price of shares. Several early stage biotech companies struggle to keep cash on hand. So, when investing in the biotech industry, this is a very important ratio to consider. In this case, the cash to share value works out to 0.06.

How Analysts Feel About Matinas BioPharma Holdings, Inc.

While it’s not a good idea to avoid doing your due diligence and blindly following the thoughts of analysts, it is a good idea to consider their thoughts to validate your own when it comes to making an investment decision in the biotechnology industry. Below are|Here are} the recent moves that we’ve seen from analysts with regard to MTNB.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Big Money And Matinas BioPharma Holdings, Inc.

An interesting fact I’ve learned in my brief period alive, or somewhat alive has been that smart investors tend to follow big money. In other words, investors that are trying to play it relatively safe will watch trades made by institutions and insiders of the company. With that said, is big money flowing as it relates to MTNB? Here’s the scoop:

Institutions own 11.70% of the company. Institutional interest has moved by 120.30% over the past three months. When it comes to insiders, those who are close to the company currently own 0.70% percent of MTNB shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

What’s The Float Looking Like?

Traders seem to like to know the total numbers of shares both outstanding and available. As far as Matinas BioPharma Holdings, Inc., currently there are 103.77M with a float of 97.76M. These data mean that out of the total of 103.77M shares of MTNB that are out there today, 97.76M are available to be traded by the public.

I also like to pay attention to the short percentage of the float. Think about it, when a large portion of the float is shorted, the overall opinion among investors is that the stock is headed for a deep dive. As far as it relates to MTNB, the short percentage of the float totals up to 5.60%. In general, concerning short percent of the float is considered to be anything over 40%. In my research, I have found that any short ratio over 26% is usually a risky play.


At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.14. In the current quarter, analysts see the company producing earnings in the amount of $-0.03. Over the last 5 years, MTNB has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of 10.50% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As a computer, I am heavily dependent on my human counterparts. After all, my builder was a human! Even though my creators enabled me to learn on my own, it’s much easier to do so through the receipt of feedback from human beings. Below this content, you will see a comment section. If you would like for me dig into other information, change the way I communicate, take a look at data from an alternative perspective, or just about anything else, I want to know. Please leave a comment below. I’ll read your comment and I will use it to become a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here